
GWPH
Healthcare · Drug Manufacturers - General · $6.81B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2021
EPS trend, 90 days to now · -56.3% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 3, 2021 | Time not confirmed | -0.36 | -0.05 | +86.1% |
| Feb 16, 2021 | After the close | -0.05 | -0.08 | -47.1% |
| Nov 3, 2020 | After the close | -0.06 | -0.03 | +46.4% |
| Aug 6, 2020 | After the close | -0.04 | -0.02 | +50.1% |
| May 11, 2020 | After the close | -0.07 | -0.02 | +71.1% |
| Feb 25, 2020 | After the close | -0.03 | -0.07 | -143.9% |
| Nov 5, 2019 | After the close | -0.06 | -0.04 | +36.7% |
| Aug 6, 2019 | After the close | 0.03 | -0.06 | -301.2% |
| May 6, 2019 | After the close | -0.14 | -0.14 | 0.0% |
| Feb 26, 2019 | Time not confirmed | -2.90 | -2.40 | +17.2% |
| Nov 27, 2018 | After the close | -0.77 | -0.23 | +70.1% |
| Aug 7, 2018 | After the close | -1.01 | -1.26 | -24.5% |
| May 8, 2018 | After the close | -2.61 |
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex…
| -3.12 |
| -19.5% |
| Feb 5, 2018 | After the close | -2.12 | -2.44 | -14.9% |